The Swiss-American bioinformatics company touts its networks of multimodal data and numerous partnerships as it looks to support "data-driven medicine."
Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.
The company will provide proprietary algorithms for analyzing omics and imaging data to define predictors of drug response and identify new biomarkers.
Transcriptomic and multi-omic data spanning more than 10,000 samples helped map "immunogenomic" interactions that may inform treatment outcomes and targets.
Investigators are planning to further validate specific applications, such as prediction of lung and lymphoma cancer subtypes, in independent sample sets.
The accelerated approval is based on results from two cohorts of a Phase II, single-arm trial in which EZH2-mutated patients had an overall response rate of 69 percent.
